ACCUConfCTAD: Complete Guide to Class Template Argument Deduction – Nina Ranns – ACCU 2024
YouTube
CTAD: Complete Guide to Class Template Argument Deduction – Nina Ranns – ACCU 2024
CTAD: Complete Guide to Class Template Argument Deduction - Nina Ranns - ACCU 2024
CTAD: Complete Guide to Class Template Argument Deduction – Nina Ranns – ACCU 2024
CTAD: Complete Guide to Class Template Argument Deduction - Nina Ranns - ACCU 2024
CTAD: Complete Guide to Class Template Argument Deduction – Nina Ranns – ACCU 2024
CTAD: Complete Guide to Class Template Argument Deduction – Nina Ranns – ACCU 2024
cbn2AlzeCure Pharma's presentation (re: Preventive #Treatment Against Alzheimer's) given at 2022 #CTAD Conference is now publicly available on their website, with additional data, here: https://www.alzecurepharma.se/en/presentations-and-interviews/ #alzheimers
Domingos Henrique"It is time to close the book on the amyloid hypothesis", it is one of the conclusions. Good thread.
---
RT @schrag_matthew
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:
https://twitter.com/schrag_matthew/status/1597860167806111744
---
RT @schrag_matthew
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:
https://twitter.com/schrag_matthew/status/1597860167806111744
Carolyn Barber, MDR/T by @schrag_matthew (neuro/AD expert):
“New Alzheimer’s drug not game changer:
(From neuro MD focused on AD)
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points: 1) This trial is much better than the frustrating data associated with Aducanumab. Demographics are well balanced between groups 2/8